hVIVO plc (LON:HVO - Get Free Report) shares were down 46.3% on Saturday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). Approximately 83,062,000 shares were traded during trading, an increase of 2,325% from the average daily volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).
Wall Street Analyst Weigh In
Separately, Shore Capital reiterated a "buy" rating on shares of hVIVO in a research note on Friday.
View Our Latest Report on hVIVO
hVIVO Trading Up 23.0%
The stock has a market cap of £75.71 million, a price-to-earnings ratio of 4.41 and a beta of 0.97. The firm's 50 day moving average is GBX 16.08 and its two-hundred day moving average is GBX 17.93. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.
hVIVO (LON:HVO - Get Free Report) last released its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Equities analysts anticipate that hVIVO plc will post 1.5492958 EPS for the current year.
Insider Buying and Selling
In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($705,204.31). 14.03% of the stock is owned by company insiders.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
